Published on: October 16, 2026
Strong scientific evidence does not always lead to clear business decisions, especially as a company approaches a major growth or commercialization milestone. For life sciences executive recruiters, the challenge is assessing whether an executive can translate complex evidence into decisions that resonate across patients, physicians, regulators, payers, and the market.
The Gap Between Strong Science and Market Readiness
Life-sciences organizations often have no shortage of technical expertise.
Researchers understand the underlying science. Clinical teams interpret trial data. Regulatory professionals understand submission requirements. Medical affairs teams evaluate scientific evidence. Commercial leaders understand markets and customer behavior.
The difficulty can emerge between these disciplines.
Scientific findings do not automatically become a commercial strategy. A statistically meaningful result still needs to be interpreted in the context of the patient population, treatment landscape, regulatory pathway, clinical differentiation, competitive environment, and practical adoption considerations.
Life sciences executive recruiters at the intersection of these issues needs to understand enough of the underlying science to ask useful questions while also understanding what different stakeholders need from the evidence.
That is a very different capability from simply having experience in either R&D or commercial leadership.
Why Executive Searches Should Examine Translation Capability
Traditional executive hiring criteria often emphasize:
- Years of industry experience
- Functional leadership
- Therapeutic-area knowledge
- Commercial responsibility
- Scientific credentials
- Product-launch experience
These factors can all be relevant. But they do not necessarily reveal whether an executive can translate complex scientific information into coordinated organizational action.
Consider a company preparing to advance a new therapy.
The scientific team may describe the mechanism of action. Clinical development may present efficacy and safety data. Medical affairs may identify evidence gaps. Regulatory teams may outline requirements. Commercial leaders may assess the competitive landscape.
An executive has to connect those perspectives.
The challenge is not becoming the technical expert in every discipline. It is understanding which questions need to be asked when one discipline’s conclusions affect another discipline’s decisions.
That capability can be particularly valuable during periods of organizational transition.
What Scientific-to-Commercial Translation Actually Looks Like
Translation is sometimes misunderstood as simplifying technical information for a nontechnical audience.
At the executive level, it is more consequential than that.
It involves determining what scientific information means for a business decision and ensuring that the organization does not lose important context during that transition.
For example, an executive may need to determine:
- Whether a clinical finding creates meaningful differentiation or merely statistical differentiation.
- Which evidence gaps could affect adoption.
- Whether additional research would materially change the commercial strategy.
- How scientific uncertainty should influence investment decisions.
- Which claims can appropriately be supported by available evidence.
- How regulatory considerations affect commercial planning.
- Whether internal teams are interpreting the same evidence consistently.
The executive does not necessarily need to perform the underlying scientific analysis.
The leadership requirement is to understand enough to make better decisions about what the analysis means.
A Better Way to Evaluate Candidates
Life sciences executive recruiters can make this capability more visible by asking candidates to reconstruct a significant decision from their previous experience.
Rather than asking, “Tell us about a successful product launch,” a search process could examine the reasoning behind the launch.
For example:
What did the scientific evidence initially suggest? : This establishes the candidate’s understanding of the underlying information.
What changed as additional evidence became available? : This reveals whether the candidate can adapt rather than defend an existing position.
Which functions disagreed about the implications of the evidence? : This exposes how the candidate navigates competing interpretations.
How did the scientific findings change the business decision?: This tests translation rather than communication alone.
What did you decide not to do, and why? : This can reveal whether the executive understands opportunity cost and uncertainty.
These questions are particularly useful because they focus on the candidate’s decision process instead of allowing the interview to become a list of accomplishments.
The Importance of Evidence Discipline
Scientific-to-commercial translation also has an important evidence-management component.
The FDA’s guidance on promotional communications for prescription drugs emphasizes the importance of presenting information in a way that is truthful, non-misleading, and appropriately supported. That broader principle reinforces why executives working across scientific and commercial functions need to understand the distinction between what evidence establishes, what it suggests, and what remains uncertain.
For executive hiring, this creates another useful assessment dimension.
A leader should be able to recognize when enthusiasm for a promising program begins to outrun the available evidence.
That does not mean avoiding ambitious commercial decisions.
It means understanding where the evidence is strong, where assumptions are being made, and where additional validation could materially change the decision.
When Scientific and Commercial Priorities Diverge
One of the strongest tests of executive judgment occurs when scientific and commercial incentives point in different directions.
- A commercial team may want to accelerate a launch.
- A clinical team may believe additional evidence is needed.
- Regulatory professionals may identify uncertainty around a proposed indication.
- Medical affairs may see an important unmet evidence need.
- Finance may be evaluating whether additional investment is justified.
- None of these perspectives is automatically the “right” answer.
The executive’s role is to understand the implications of each and establish a decision framework that reflects the organization’s objectives, evidence, risk tolerance, and obligations.
This is why executive search should investigate how candidates handled disagreement.
A useful candidate may not describe every previous decision as successful. More revealing evidence can come from a situation where the candidate changed course because new scientific information challenged the original strategy.
Look Beyond the Traditional Launch Resume
A candidate does not necessarily need to have personally led a blockbuster launch to demonstrate scientific-to-commercial leadership.
Relevant evidence can come from other experiences, including:
- Redirecting a development program after new data emerged
- Changing a target population based on clinical findings
- Aligning R&D and commercial teams around an evidence strategy
- Revising investment priorities after scientific uncertainty increased
- Coordinating medical, regulatory, and commercial perspectives
- Explaining technical risk to a board or investor audience
- Establishing governance for decisions involving scientific and commercial stakeholders
These examples can reveal whether an executive understands the relationship between evidence and action.
That is particularly valuable when hiring for companies whose most important decisions are still ahead of them.
The Executive’s Role Changes as a Program Matures
Scientific-to-commercial translation becomes especially important as a product progresses through development.
Early-stage organizations may prioritize scientific exploration and platform validation.
Later-stage organizations may need stronger integration between clinical development, regulatory strategy, medical affairs, manufacturing, market access, and commercialization.
The executive profile should therefore reflect the organization’s actual point of transition.
A leader who is highly effective in an exploratory research environment may have a different skill set from one needed to coordinate a late-stage development program. Neither profile is inherently superior. The relevant question is whether the executive’s experience matches the organization’s current decision environment.
That is where life sciences executive recruiters can move beyond title matching and evaluate the specific translation burden of the role.
Build the Search Around the Decisions Ahead
The most useful executive search brief may begin with the organization’s next five major decisions rather than its existing organizational chart.
- What scientific questions remain unresolved?
- Which milestones could materially change the company’s strategy?
- Where will R&D, clinical, regulatory, medical, and commercial priorities intersect?
- Which decisions will require the executive to interpret evidence rather than simply receive functional recommendations?
Answering those questions creates a more precise definition of leadership capability.
The resulting candidate profile can then emphasize evidence-based decision-making, cross-functional translation, scientific fluency, commercial judgment, and the ability to operate constructively when information remains incomplete.
Why Translation Is Becoming an Executive Capability
As life sciences organizations become increasingly specialized, senior leaders cannot realistically be the deepest technical experts in every discipline around the table.
Their value increasingly comes from connecting those disciplines without flattening the complexity that makes each one important.
That means the strongest executive assessment may not ask whether a candidate is “scientific” or “commercial.” It should examine whether the candidate can move accurately between the two.
For life sciences executive recruiters, that creates a more nuanced way to evaluate leadership potential. The objective is not simply to identify someone with pharmaceutical experience or a successful launch on a résumé. It is to determine whether the executive can interpret complex evidence, challenge assumptions, connect functional perspectives, and turn scientific understanding into disciplined organizational decisions.
